FDA Clinical Trial Inspection Process Detailed In Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
A new draft 1guidance explains CDRH's process for ensuring the integrity of data included in device premarket approval submissions
You may also be interested in...
FDA Spells Out Details Of Premarket Clinical Trial Inspections
A final guidance document released by FDA Jan. 8 gives the timetable that device makers can expect when PMA applications and supplements are reviewed by the device center's bioresearch monitoring division
FDA Spells Out Details Of Premarket Clinical Trial Inspections
A final guidance document released by FDA Jan. 8 gives the timetable that device makers can expect when PMA applications and supplements are reviewed by the device center's bioresearch monitoring division
“For Cause” Inspections Find Galloping Clinical Trial Violation Rate
The violation rate for clinical trial sponsors shot up in fiscal year 2007, hitting a 10-year high, with FDA finding many of the problems during inspections triggered by complaints, according to CDRH